Overview
TaiRx Inc is a Taiwan-based biotechnology company headquartered in Taipei, Taiwan, dedicated to developing disease-modifying therapies for neurodegenerative disorders, particularly Alzheimer's disease (AD) and Parkinson's disease (PD)[@tairx2026]. Founded in 2003, TaiRx has established itself as a leading CNS drug development company in Taiwan, leveraging proprietary small molecule platforms and advanced drug delivery technologies to address the growing burden of neurodegenerative diseases in aging populations[@taiwan2026].
Company Details
| Attribute | Details |
|-----------|---------|
| Headquarters | Taipei, Taiwan (Nankang Biotechnology Park) |
| Founded | 2003 |
| Focus Areas | Neurodegenerative diseases, CNS disorders, Alzheimer's disease, Parkinson's disease |
| Approach | Small molecule therapeutics, CNS drug delivery, protein aggregation inhibitors |
| Technology Platform | [Blood-brain barrier](/entities/blood-brain-barrier) (BBB) penetrating small molecules |
| Website | tairx.com.tw |
| Stock Symbol | Taiwan OTC |
Small Molecule CNS Therapeutics
TaiRx's proprietary platform focuses on developing small molecules specifically designed to cross the blood-brain barrier (BBB) and target key pathological mechanisms in neurodegenerative diseases[@pardridge2014]:
Key Platform Capabilities:
...Overview
TaiRx Inc is a Taiwan-based biotechnology company headquartered in Taipei, Taiwan, dedicated to developing disease-modifying therapies for neurodegenerative disorders, particularly Alzheimer's disease (AD) and Parkinson's disease (PD)[@tairx2026]. Founded in 2003, TaiRx has established itself as a leading CNS drug development company in Taiwan, leveraging proprietary small molecule platforms and advanced drug delivery technologies to address the growing burden of neurodegenerative diseases in aging populations[@taiwan2026].
Company Details
| Attribute | Details |
|-----------|---------|
| Headquarters | Taipei, Taiwan (Nankang Biotechnology Park) |
| Founded | 2003 |
| Focus Areas | Neurodegenerative diseases, CNS disorders, Alzheimer's disease, Parkinson's disease |
| Approach | Small molecule therapeutics, CNS drug delivery, protein aggregation inhibitors |
| Technology Platform | [Blood-brain barrier](/entities/blood-brain-barrier) (BBB) penetrating small molecules |
| Website | tairx.com.tw |
| Stock Symbol | Taiwan OTC |
Small Molecule CNS Therapeutics
TaiRx's proprietary platform focuses on developing small molecules specifically designed to cross the blood-brain barrier (BBB) and target key pathological mechanisms in neurodegenerative diseases[@pardridge2014]:
Key Platform Capabilities:
BBB Permeability Optimization: Advanced medicinal chemistry techniques to enhance CNS penetration
Novel Scaffold Development: Proprietary chemical entities targeting protein aggregation
ADME Optimization: Pharmacokinetic properties optimized for chronic dosing
Target Engagement: High-affinity binding to disease-relevant protein targetsDrug Delivery Technology
TaiRx has developed proprietary drug delivery technologies to enhance CNS drug delivery[@shoji2021]:
- Lipid-based formulations: enhanced brain penetration
- Nanoparticle delivery systems: Targeted CNS delivery
- Prodrug approaches: Improved bioavailability and brain uptake
Parkinson's Disease Program
Therapeutic Targets
TaiRx's PD program focuses on targeting multiple pathological pathways characteristic of Parkinson's disease[@spillantini2017]:
| Target | Mechanism | Development Stage |
|--------|-----------|-------------------|
| Alpha-synuclein aggregation | Inhibitor of α-syn oligomerization | Preclinical |
| Neuroinflammation | Microglial activation modulator | Research |
| Mitochondrial dysfunction | Complex I protector | Research |
Alpha-Synuclein Program
The company's lead PD program targets alpha-synuclein (α-syn) aggregation, a hallmark pathological feature of Parkinson's disease and related synucleinopathies[@bridi2023]:
- Mechanism: Small molecule inhibitors of α-synuclein oligomerization and fibril formation
- Rationale: Preventing the formation of toxic oligomers and Lewy bodies
- Preclinical data: Evidence of reduced α-syn pathology in cellular and animal models
- Next steps: IND-enabling studies
Neuroinflammation Modulation
TaiRx is developing therapies targeting neuroinflammation, a key contributor to PD progression[@chen2022]:
- [Microglia](/cell-types/microglia)l activation inhibitors
- Cytokine modulation approaches
Alzheimer's Disease Program
TaiRx's AD program includes [amyloid-beta](/proteins/amyloid-beta) (Aβ) targeting therapies[@karran2011]:
- Aβ aggregation inhibitors: Prevent toxic oligomer formation
- Amyloid plaques: Reduce plaque burden in preclinical models
Tau Pathology Program
The company is also developing therapies targeting [tau](/proteins/tau) pathology[@ballard2021]:
- Tau aggregation inhibitors: Prevent NFT formation
- Kinase inhibitors: Target pathogenic phosphorylation
Pipeline Overview
| Program | Indication | Target | Stage |
|---------|------------|--------|-------|
| TaiRx-PD-001 | Parkinson's Disease | α-synuclein | Preclinical |
| TaiRx-PD-002 | Parkinson's Disease | Neuroinflammation | Research |
| TaiRx-AD-001 | Alzheimer's Disease | Amyloid-beta | Preclinical |
Research and Development
Internal Research Capabilities
TaiRx maintains internal R&D facilities in Taiwan with capabilities in[@taiwan2026a]:
- Medicinal chemistry
- In vitro pharmacology
- In vivo pharmacology models
- ADMET profiling
- Formulation development
Preclinical Models
The company utilizes various preclinical models for drug development:
- Cellular models: α-syn aggregation cell models, dopaminergic neuron cultures
- Animal models: MPTP-induced PD model, 6-OHDA model, AAV-α-syn models
- Behavioral assessments: Rotarod, cylinder test, gait analysis
Collaborations and Partnerships
Academic Collaborations
TaiRx collaborates with leading Taiwanese research institutions[@national2026]:
- National Taiwan University (NTU): PD drug discovery and clinical translation
- Academia Sinica: Basic neurodegeneration research
- Taipei Medical University: Clinical biomarkers and outcome measures
Government Funding
TaiRx has received support from Taiwan's Ministry of Economic Affairs and National Science and Technology Council.
Competitive Landscape
TaiRx competes with global biotechnology companies developing PD therapeutics such as Prothena, Acumen, Neuraly, and Prevail[@prothena2026].
Market Opportunity
Parkinson's Disease Market
The global PD market represents significant opportunity[@dorsey2023]:
- Over 10 million patients worldwide
- Limited disease-modifying therapies available
- Growing prevalence with aging populations
Taiwan Strategic Position
Taiwan offers advantages for CNS drug development:
- Strong academic research in neurodegeneration
- Cost-effective R&D operations
- Strategic location for Asian clinical trials
Future Directions
TaiRx's development strategy includes advancing lead compounds toward clinical candidates, planning Phase 1/2 trials for PD, and developing biomarker-based patient selection approaches[@ali2015].
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [CNS Drug Development](/mechanisms/cns-drug-development)
- [Taiwanese Biotechnology Companies in Parkinson's Disease](/companies/taiwan-pd-biotech)
References
TaiRx Inc, Company Website (2026)
Taiwan Biotechnology Industry Association, Taiwan Biotech Industry Overview (2026)
[Pardridge WM, Blood-brain barrier drug delivery and target therapeutics (2014)](https://pubmed.ncbi.nlm.nih.gov/25142614/)
[Shoji J, et al, Development of CNS drug delivery platforms for neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33128892/)
[Spillantini MG, et al, Alpha-synuclein in Lewy body disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28752853/)
[Bridi JC, et al, Alpha-synuclein toxicity in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36550178/)
[Chen X, et al, Neuroinflammation in Parkinson's disease: therapeutic targets (2022)](https://pubmed.ncbi.nlm.nih.gov/35183579/)
[Karran E, et al, The amyloid cascade hypothesis of Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21852789/)
[Ballard C, et al, Tau and Alzheimer's disease: an update (2021)](https://pubmed.ncbi.nlm.nih.gov/34417394/)
Taiwan Ministry of Economic Affairs, Biotechnology Industry Development Plan (2026)
National Taiwan University, Neuroscience Research Programs (2026)
Prothena Corporation, Parkinson's Disease Pipeline (2026)
[Dorsey ER, et al, Global, regional, and national burden of Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37771385/)
[Ali M, et al, Drug development for neurodegenerative diseases: challenges and opportunities (2015)](https://pubmed.ncbi.nlm.nih.gov/25829206/)